X
[{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Zucara Therapeutics"},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Zucara Therapeutics"},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Zucara Therapeutics"},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zucara Therapeutics Reports Positive Results from Phase 1b Trial of ZT-01","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Zucara Therapeutics"},{"orgOrder":0,"company":"Wellbeing Digital Sciences","sponsor":"Nova Mentis Life Science Corp","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wellbeing Subsidiary KGK Science Announces Psilocybin Microdose Capsule Formulation to be Submitted to Health Canada for Phase 2A Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Wellbeing Digital Sciences"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
The psilocybin 1.5mg capsules are available for potential therapeutic use in non-ASD clinical trials, including but not limited to diabetes, heart disease, cancer, and post-traumatic stress disorder.
Lead Product(s):
Psilocybine
Therapeutic Area: Endocrinology
Product Name: Undisclosed
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Nova Mentis Life Science Corp
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 06, 2022
Details:
Data from 18 subjects that completed all three hypoglycemic challenge (clamp) procedures demonstrated that nearly 90% of subjects had a meaningful increase in glucagon following ZT-01 compared to placebo.
Lead Product(s):
ZT-01
Therapeutic Area: Endocrinology
Product Name: ZT-01
Highest Development Status: Phase I
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 22, 2022
Details:
Other study objectives include further evaluation of the safety and tolerability of ZT-01 and evaluation of symptoms and other hormones related to hypoglycemia. Topline results are expected in the first quarter of 2022.
Lead Product(s):
ZT-01
Therapeutic Area: Endocrinology
Product Name: ZT-01
Highest Development Status: Phase I
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 28, 2021
Details:
ZT-01, a first-in-class, once-daily therapeutic to prevent insulin-induced hypoglycemia in patients using insulin therapy. ZT-01 is designed to inhibit somatostatin, and restores glucagon secretion to prevent hypoglycemia.
Lead Product(s):
ZT-01
Therapeutic Area: Endocrinology
Product Name: ZT-01
Highest Development Status: Phase I
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 26, 2021
Details:
The study employs a single ascending dose (“SAD”) and multiple ascending dose (“MAD”) trial design and will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZT-01.
Lead Product(s):
ZT-01
Therapeutic Area: Endocrinology
Product Name: ZT-01
Highest Development Status: Phase I
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 29, 2020